Parainfluenza Virus Lower Respiratory Tract Disease After Hematopoietic Cell Transplant: Viral Detection in the Lung Predicts Outcome

Sachiko Seo,1 Hu Xie,2 Angela P. Campbell,1,2,3,4 Jane M. Kuypers,1,5 Wendy M. Leisenring,2 Janet A. Englund,3,4 and Michael Boeckh1,2,6

1Vaccine and Infectious Disease Division and 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; 3Department of Pediatrics, University of Washington, Seattle; 4Pediatric Infectious Diseases Division, Seattle Children’s Hospital, Washington; and Departments of 5Laboratory Medicine and 6Medicine, University of Washington, Seattle

Background. Parainfluenza virus (PIV) commonly infects patients following hematopoietic cell transplantation (HCT), frequently causing lower respiratory tract disease (LRTD). The definition of LRTD significantly differs among studies evaluating the impact of PIV after HCT.

Methods. We retrospectively evaluated 544 HCT recipients with laboratory-confirmed PIV and classified LRTD into 3 groups: possible (PIV detection in upper respiratory tract with new pulmonary infiltrates with/without LRTD symptoms), probable (PIV detection in lung with LRTD symptoms without new pulmonary infiltrates), and proven (PIV detection in lung with new pulmonary infiltrates with/without LRTD symptoms).

Results. Probabilities of 90-day survival after LRTD were 87%, 58%, and 45% in possible, probable, and proven cases, respectively. Patients with probable and proven LRTD had significantly worse survival than those with upper respiratory tract infection (probable: hazard ratio [HR], 5.87 [P < .001]; proven: HR, 9.23 [P < .001]), whereas possible LRTD did not (HR, 1.49 [P = .27]). Among proven/probable cases, oxygen requirement at diagnosis, low monocyte counts, and high-dose steroid use (>2 mg/kg/day) were associated with high mortality in multivariable analysis.

Conclusions. PIV LRTD with viral detection in lungs (proven/probable LRTD) was associated with worse outcomes than was PIV LRTD with viral detection in upper respiratory samples alone (possible LRTD). This new classification should impact clinical trial design and permit comparability of results among centers.

Keywords. parainfluenza virus; lower respiratory tract disease; hematopoietic cell transplant; classification.
We hypothesized that the differences in definitions of LRTD used in prior studies are a major determinant of the observed variability in outcome. The purpose of this study was to classify PIV LRTD according to the site of virologic detection and clinical manifestations, and to compare clinical outcomes among the groups. Moreover, we examined various risk factors for overall mortality and death due to respiratory failure.

METHODS

Study Design
This retrospective cohort study includes patients who first received transplant between December 1990 and December 2011 at the Fred Hutchinson Cancer Research Center (FHCRC) and had documented PIV infection after HCT that was virologically detected at the University of Washington Virology Laboratories (a subset of patients were included in a previously published report [4]). Only an individual’s first episode of PIV infection was analyzed. Patients’ demographic data and transplant information closest to the PIV infection were retrieved from the FHCRC database, and other data related to the clinical course of PIV infections were collected by medical record review. The study was approved by the Institutional Review Board at FHCRC.

Definitions
PIV detection was performed by conventional culture, direct fluorescent antibody tests, and/or reverse transcription polymerase chain reaction (RT-PCR) assay in respiratory samples. PIV upper respiratory tract infection (URTI) was defined as PIV detection in a nasopharyngeal or sputum sample, with URTI symptoms but no new pulmonary infiltrates. LRTD was divided into 3 groups: possible, probable, and proven. Possible LRTD was defined as PIV detection in a nasopharyngeal or sputum sample with new pulmonary infiltrates (but without confirmation of PIV in the lower respiratory tract) with or without LRTD signs or symptoms (eg, cough, wheezing, rales, tachypnea, shortness of breath, dyspnea, or hypoxia). Probable LRTD was defined as PIV detection in a bronchoalveolar lavage (BAL) or lung biopsy sample with LRTD symptoms, with or without pulmonary function decline, and without new pulmonary infiltrates. The definition of proven LRTD was PIV detection in a BAL or biopsy sample with new pulmonary infiltrates with or without LRTD symptoms.

Viral load was determined by quantitative RT-PCR using stored frozen repository samples [13]. Peak steroid dose was recorded from the period within 2 weeks before PIV infection in patients with URTI. In PIV LRTD cases, peak steroid doses were recorded from within 2 weeks before and after LRTD diagnosis, respectively, and exact steroid dose at 1 month after diagnosis was also collected. Death caused by respiratory failure was defined as any death caused exclusively or predominantly by respiratory failure [14].

Statistical Analysis
Patients’ demographic characteristics were summarized and compared among disease categories using \( \chi^2 \) or Fisher exact test for categorical variables, and Wilcoxon rank-sum test for continuous variables (as appropriate). Wilcoxon rank-sum or Kruskal-Wallis test was utilized for comparisons of continuous variables. The probability of overall survival was estimated using the Kaplan-Meier method. The probability of mortality caused by respiratory failure and incidence of mechanical ventilation were estimated by cumulative incidence curves, treating death due to other causes as a competing risk event. The log-rank test was used to compare univariable hazards of time-to-event outcomes between disease categories. Cox proportional hazards models were used to evaluate unadjusted and adjusted hazard ratios (HRs) for mortality or respiratory mortality, and associated 95% confidence intervals (CIs) were reported. Variables with \( P \leq .1 \) in the univariable models were candidates for multivariable models. Two-sided \( P \) values <.05 were considered statistically significant.

RESULTS

Patient Characteristics
A total of 544 patients had PIV infection following HCT; 345 (63%) and 199 (37%) had URTI and LRTD disease, respectively. LRTD classification of patients included 78 (39%) possible, 19 (10%) probable, and 102 (51%) proven cases of LRTD. Characteristics of each PIV infection group are shown in Table 1. The median time to PIV infection and PIV LRTD after HCT was 71.5 days (range, 0–3140 days) and 78 days (range, 3–3140), respectively.

Mortality in Each Disease Category
The probabilities of overall survival and mortality from respiratory failure at 90 days following PIV diagnosis in patients with URTI or LRTD are shown in Figure 1A and 1B (overall survival: 91% in URTI, 62% in LRTD; mortality from respiratory failure: 2.5% in URTI, 28% in LRTD) (\( P < .001 \) for both comparisons). Next, we analyzed the probabilities of overall survival and death caused by respiratory failure among LRTD cases, comparing the 3 disease categories: possible, probable, and proven (Figure 1C and 1D). The probabilities of 90-day survival after PIV LRTD were 87%, 58%, and 45% in possible, probable and proven cases, respectively \( (P < .001 \); Figure 1C). The presence of LRTD symptoms in possible or proven cases resulted in worse survival than when no LRTD symptoms were present (Supplementary Figure 1A and 1B). Mortality rates in each group are shown in Table 2.
| Characteristic                      | Total (N = 544) | URTI (n = 345) | Possible (n = 78) | Probable (n = 19) | Proven (n = 102) | P Value |
|-----------------------------------|----------------|---------------|------------------|------------------|-----------------|---------|
| **Sex**                           |                |               |                  |                  |                 | .11     |
| Male                              | 321 (59)       | 201 (58)      | 40 (51)          | 15 (79)          | 65 (64)         |         |
| Female                            | 223 (41)       | 144 (42)      | 38 (49)          | 4 (21)           | 37 (36)         |         |
| **Age at transplant, y**          |                |               |                  |                  |                 | .14     |
| ≤20                               | 105 (19)       | 71 (20)       | 19 (24)          | 3 (16)           | 12 (12)         |         |
| 21–60                             | 365 (67)       | 227 (66)      | 45 (58)          | 15 (79)          | 78 (77)         |         |
| >60                               | 74 (14)        | 47 (14)       | 14 (18)          | 1 (5)            | 12 (12)         |         |
| **Transplant year**               |                |               |                  |                  |                 | <.001   |
| 1990–2000                         | 269 (49)       | 175 (51)      | 25 (32)          | 15 (79)          | 54 (53)         |         |
| 2001–2011                         | 275 (51)       | 170 (49)      | 53 (68)          | 4 (21)           | 48 (47)         |         |
| **Transplant No.**                |                |               |                  |                  |                 | .55     |
| First                             | 488 (89)       | 311 (90)      | 69 (88)          | 19 (100)         | 89 (87)         |         |
| Second                            | 53 (10)        | 31 (9)        | 9 (12)           | 0 (0)            | 13 (13)         |         |
| Third                             | 3 (1)          | 3 (1)         | 0 (0)            | 0 (0)            | 0 (0)           |         |
| **Cell source**                   |                |               |                  |                  |                 | <.001   |
| Bone marrow                       | 251 (46)       | 168 (49)      | 23 (30)          | 16 (84)          | 44 (43)         |         |
| Peripheral blood stem cell        | 269 (49)       | 167 (48)      | 46 (59)          | 3 (16)           | 53 (52)         |         |
| Cord blood                        | 24 (4)         | 10 (3)        | 9 (11)           | 0 (0)            | 5 (5)           |         |
| **Donor type**                    |                |               |                  |                  |                 | <.001   |
| Autologous                        | 104 (19)       | 71 (21)       | 16 (21)          | 0 (0)            | 17 (17)         |         |
| Related                           | 202 (37)       | 135 (39)      | 23 (29)          | 8 (42)           | 36 (35)         |         |
| Unrelated                         | 238 (44)       | 139 (40)      | 39 (50)          | 11 (58)          | 49 (48)         |         |
| **Conditioning regimen**          |                |               |                  |                  |                 | .83     |
| MAC                               | 447 (82)       | 281 (82)      | 63 (78)          | 16 (84)          | 87 (85)         |         |
| RIC                               | 97 (18)        | 64 (18)       | 15 (22)          | 3 (16)           | 15 (15)         |         |
| **Days between transplant and PIV infection** | | | | | | .036   |
| ≤30                               | 119 (22)       | 66 (19)       | 22 (28)          | 3 (16)           | 28 (28)         |         |
| 31–365                            | 349 (64)       | 238 (69)      | 40 (51)          | 14 (74)          | 57 (56)         |         |
| >365                              | 76 (14)        | 41 (12)       | 16 (21)          | 2 (10)           | 17 (17)         |         |
| **PIV type**                      |                |               |                  |                  |                 | <.001   |
| PIV-1                             | 52 (10)        | 26 (8)        | 16 (21)          | 1 (5)            | 9 (9)           |         |
| PIV-2                             | 30 (5)         | 24 (7)        | 3 (4)            | 0 (0)            | 3 (3)           |         |
| PIV-3                             | 434 (80)       | 275 (80)      | 53 (68)          | 17 (90)          | 89 (87)         |         |
| PIV-4                             | 22 (4)         | 16 (5)        | 5 (6)            | 1 (5)            | 0 (0)           |         |
| Unclassified                      | 6 (1)          | 4 (1)         | 1 (1)            | 0 (0)            | 1 (1)           |         |
| **Quantitative viral load, median (range)** | 5.0 × 10⁶ (1.0 × 10²–1.1 × 10⁹) | 4.8 × 10⁶ (1.0 × 10²–3.3 × 10⁹) | 7.4 × 10⁶ (2.7 × 10⁵–1.1 × 10⁹) | .51   |
| **Copathogen**                    |                |               |                  |                  |                 | <.001   |
| No                                | 457 (84)       | 313 (91)      | 61 (78)          | 16 (84)          | 67 (66)         |         |
| Yes                               | 87 (16)        | 32 (9)        | 17 (22)          | 3 (16)           | 35 (34)         |         |
| **Oxygen at diagnosis**           |                |               |                  |                  |                 | <.001   |
| No                                | 472 (87)       | 342 (99)      | 63 (81)          | 13 (68)          | 54 (53)         |         |
| Yes                               | 72 (13)        | 3 (1)         | 15 (19)          | 6 (32)           | 48 (47)         |         |
| **White blood cell count**        |                |               |                  |                  |                 | <.001   |
| >1000 cells/µL                    | 447 (85)       | 299 (90)      | 59 (76)          | 19 (100)         | 70 (69)         |         |
| ≤1000 cells/µL                    | 82 (15)        | 32 (10)       | 19 (24)          | 0 (0)            | 31 (31)         |         |

*PIV LRTD After HCT* • *CID 2014:58 (15 May) • 1359
Univariable analysis of risk factors for overall mortality demonstrated that probable and proven LRTD was significantly associated with higher mortality compared with URTI (hazard ratio [HR], 5.87; 95% confidence interval [CI], 2.7–12.8; P < .001 in probable cases, and HR, 9.23; 95% CI, 5.9–14.3; P < .001 in proven cases), whereas possible LRTD was not (HR, 1.49; 95% CI, .7–3.0; P = .27). Similar results were obtained in the univariable analysis of risk factors for mortality from respiratory failure (HR, 2.56; 95% CI, 9.23; 95% CI, 5.9–14.3; P < .001 in possible cases; HR, 4.95; 95% CI, 1.1–22.9; P = .041 in probable cases; HR, 24.4; 95% CI, 11.9–50.0; P < .001 in proven cases). Because only 10 patients with possible LRTD and 8 with probable LRTD died by day 90 after diagnosis, it was not feasible to evaluate the impact of each disease category on mortality in multivariable analyses.

**Table 1 continued.**

| Characteristic       | Total (N = 544) | URTI (n = 345) | Possible (n = 78) | Probable (n = 19) | Proven (n = 102) | P Value |
|----------------------|----------------|----------------|-------------------|-------------------|-----------------|---------|
| Lymphocyte count     |                |                |                   |                   |                 |         |
| >300 cells/µL        | 332 (64)       | 224 (65)       | 44 (58)           | 11 (58)           | 53 (53)         | .026    |
| ≤300 cells/µL        | 191 (36)       | 104 (32)       | 32 (42)           | 8 (42)            | 47 (47)         |         |
| Neutrophil count     |                |                |                   |                   |                 | <.001   |
| >1000 × 10⁶ cells/L  | 407 (77)       | 270 (82)       | 56 (73)           | 18 (95)           | 63 (63)         |         |
| ≤1000 × 10⁶ cells/L  | 120 (23)       | 61 (18)        | 21 (27)           | 1 (5)             | 37 (37)         |         |
| Monocyte count       |                |                |                   |                   |                 | <.001   |
| >100 × 10⁶ cells/L   | 381 (73)       | 266 (81)       | 53 (70)           | 11 (58)           | 51 (51)         |         |
| ≤100 × 10⁶ cells/L   | 141 (27)       | 61 (19)        | 23 (30)           | 8 (42)            | 49 (49)         |         |
| Steroid dose before diagnosis<sup>a</sup> | | | | | | |
| No                   | 242 (47)       | 160 (50)       | 40 (53)           | 5 (26)            | 37 (38)         |         |
| <1 mg/kg             | 133 (26)       | 78 (24)        | 25 (34)           | 4 (21)            | 26 (26)         |         |
| 1–2 mg/kg            | 124 (24)       | 77 (24)        | 9 (12)            | 7 (37)            | 31 (32)         |         |
| >2 mg/kg             | 13 (3)         | 5 (2)          | 1 (1)             | 3 (16)            | 4 (4)           |         |
| Ribavirin use<sup>b</sup> | | | | | | <.001 |
| No                   | 483 (89)       | 336 (97)       | 73 (94)           | 12 (63)           | 62 (61)         |         |
| Yes                  | 61 (11)        | 9 (3)          | 5 (6)             | 7 (37)            | 40 (39)         |         |
| IVIG use<sup>c</sup> |                |                |                   |                   |                 | <.001   |
| No                   | 373 (69)       | 251 (73)       | 58 (74)           | 11 (58)           | 53 (52)         |         |
| Low-dose<sup>d</sup> | 138 (26)       | 89 (26)        | 17 (22)           | 3 (16)            | 29 (29)         |         |
| High-dose            | 31 (6)         | 4 (1)          | 3 (4)             | 5 (26)            | 19 (19)         |         |

All values are indicated as No. (%). Additional baseline parameters (disease risk at transplant, graft-vs-host disease prophylaxis, recipient cytomegalovirus serostatus, percentage of forced expiratory volume in 1 second/forced vital capacity before PIV infection, and percentage of predicted total lung capacity before PIV infection) were examined and did not show statistical differences between groups.

Abbreviations: IVIG, intravenous immunoglobulin; LRTD, lower respiratory tract disease; MAC, myeloablative conditioning; PIV, parainfluenza virus; RIC, reduced-intensity conditioning; URTI, upper respiratory tract infection.

<sup>a</sup> Five patients with multiple transplants had their reference transplant after 2011.

<sup>b</sup> The MAC and RIC regimens were defined as previously described [14].

<sup>c</sup> Exact P value could not be calculated.

<sup>d</sup> A copathogen was defined as a significant pathogen detected in concurrent nasopharyngeal, bronchoalveolar lavage, or lung biopsy samples, or in a blood sample obtained within 2 days of diagnosis of PIV infection.

<sup>e</sup> Ribavirin was administered as follows: aerosolized in 45 patients, systemic in 10, both in 1, and unknown in 5.

<sup>f</sup> To maintain levels of >400 mg/dL, as needed.

**Hypoxemia and Hospitalization in Each LRTD Category**

The probabilities of requiring mechanical ventilation by 28 days after PIV LRTD were 10%, 18%, and 41% in possible, probable, and proven cases, respectively (P < .001; Figure 2). Oxygen-free days in each group were shown in Table 3. Days alive without hospitalization by 28 days after PIV LRTD were longer in order of possible, probable, and proven cases (mean: 19 [SD, 10] days in possible cases, 15 [SD, 11] days in probable cases, 8.0 [SD, 9] days in proven cases, respectively, P < .001).
Figure 1. Probability of overall survival and death caused by respiratory failure. A, Kaplan-Meier estimate of overall survival according to classification of parainfluenza virus (PIV) infection in hematopoietic cell transplant (HCT) recipients ($P < .001$). B, Cumulative incidence of death caused by respiratory failure according to classification of PIV infection in HCT recipients ($P < .001$). C, Kaplan-Meier estimate of overall survival according to lower respiratory tract disease (LRTD) classification ($P < .001$). D, Cumulative incidence of death caused by respiratory failure according to LRTD classification ($P < .001$). Abbreviations: LRTD, lower respiratory tract disease; PIV, parainfluenza virus; URTI, upper respiratory tract infection.

Table 2. Mortality Rates in Each Group

| Category                              | URTI (n = 345) | LRTD Possible (n = 22) | LRTD Probable (n = 19) | LRTD Proven (n = 14) | LRTD Total (n = 88) |
|---------------------------------------|----------------|------------------------|------------------------|----------------------|---------------------|
| Positive nasopharyngeal test          | Yes            | Yes                    | Yes                    | a                    | a                   |
| Positive BAL/biopsy                  | NT/No          | NT/No                  | NT/No                  | Yes                  | Yes                 |
| Positive radiography                 | No             | Yes                    | Yes                    | No                   | Yes                 |
| Lower respiratory tract symptoms     | b              | No                     | Yes                    | No                   | Yes                 |
| Overall survival by day 90 (%)       | 91             | 100                    | 82                     | 58                   | 57                  | 43                  |
| Respiratory death by day 90 (%)      | 3              | 0                      | 9                      | 11                   | 29                  | 47                  |

Abbreviations: BAL, bronchoalveolar lavage; LRTD, lower respiratory tract disease; NT, not tested; URTI, upper respiratory tract infection.

a Any result (yes or no) or nonnasopharyngeal test.
b Any result (yes or no).
Overall survival and risk of pulmonary death when analyzed in terms of mechanical ventilation according to LRTD classification (P < .001).

**Figure 2.** Probability of mechanical ventilation after parainfluenza virus lower respiratory tract disease (LRTD). Cumulative incidence of requirements of mechanical ventilation according to LRTD classification (P < .001).

### Risk Factors for Mortality From All Causes or Respiratory Failure in Proven/Probable LRTD Cases

We focused on proven and probable LRTD cases to analyze the risk factors for mortality. A univariable analysis of risk factors for overall mortality showed that days between transplant and PIV infection, oxygen use, cell counts, and steroid dose >2 mg/kg/day before or after diagnosis were significant risk factors (Table 4). The same risk factors as well as PIV type were also significant for mortality from respiratory failure (Table 4). Among white blood cell populations, a monocyte count <100 cells/µL was identified as the most important factor for mortality in the multivariable analysis (Table 5). These results were similar to those obtained from patients with only proven LRTD, except that low monocyte counts become a significant risk factor for overall mortality in a multivariable analysis (adjusted HR [aHR], 2.01; 95% CI, 1.1–3.8; P = .029). Lower monocyte counts had a statistically significant effect on overall survival and risk of pulmonary death when analyzed in combination with oxygen requirements at diagnosis (Figure 3A and 3B).

A statistically significant difference in mortality was seen between probable and proven LRTD with symptoms (Table 4). The presence of clinical LRTD symptoms tended to be associated with worse outcome, although the effect did not reach statistical significance (Table 4).

### Association Between Steroid Dose or Antiviral Treatment and Outcomes in Proven/Probable LRTD Cases

In the univariable analysis, steroid doses >2 mg/kg/day both before and after diagnosis of PIV LRTD were significantly associated with increased mortality, whereas steroid doses <2 mg/kg/day did not have any dose-dependent effect on mortality (Table 4). Because only a small number of the patients receiving steroid doses >2 mg/kg/day died by day 90 after diagnosis, the effect of steroid dose was evaluated while adjusting only for oxygen requirement at diagnosis, which is the most important risk factor for mortality. In this adjusted model, steroid dose >2 mg/kg/day after diagnosis remained significantly associated with mortality (Table 5).

The use of ribavirin was significantly associated with reduced overall mortality, but not with mortality from respiratory failure in multivariable analyses (Table 5). Among the patients with proven LRTD, however, ribavirin did not affect the overall or respiratory failure–related mortality (aHR, 0.64; 95% CI, 0.4–1.2; P = .13 in overall mortality, and aHR, 0.96; 95% CI, 0.5–1.8; P = .91 in respiratory mortality). High-dose intravenous immunoglobulin (IVIG) also had no effect on mortality after PIV LRTD (Table 5).

### Association Between Diagnostic Method or BAL Viral Load and Outcomes in Proven/Probable LRTD Cases

Among 121 proven/probable LRTD cases, 31 (26%) patients were diagnosed using PCR alone. Although patients diagnosed with PCR alone had lower viral load (P < .001; Supplementary Figure 2A), there was no statistically significant survival advantage (Table 4).

In proven/probable LRTD cases, 48 stored BAL samples were available and tested by quantitative RT-PCR. There was no statistically significant difference between median viral load in subjects with proven and probable LRTD (Table 1, Supplementary Figure 2B). An association between viral load and mortality after PIV LRTD was not observed even after adjusting for oxygen use at diagnosis (HR, 1.03; 95% CI, 0.93–1.13; P = .60 for overall mortality, and HR, 1.09; 95% CI, 0.96–1.23; P = .19 for mortality from respiratory failure; Table 4 and data not shown).

### DISCUSSION

This study demonstrates that the clinical outcome of patients with PIV detection in the lung (which we termed “proven” or

| Table 3. Oxygen-Free Days According to Parainfluenza Virus Lower Respiratory Tract Disease Category |
|-----------------------------------------------|------------------|------------------|------------------|------------------|
| Outcome                                      | Possible | Probable | Proven | P Value   |
| Any oxygen-free days                         |          |          |       |          |
| By day 14 after PIV LRTD                     | 12 (4)   | 10 (6)   | 6 (6)  | <.0001   |
| By day 28 after PIV LRTD                     | 24 (8)   | 20 (11)  | 12 (11)| <.0001   |
| >2 L/min oxygen-free days                    |          |          |       |          |
| By day 14 after PIV LRTD                     | 13 (3)   | 11 (4)   | 9 (4)  | <.0001   |
| By day 28 after PIV LRTD                     | 26 (4)   | 22 (9)   | 18 (9) | <.0001   |

All values are presented as mean (standard deviation).

Abbreviations: LRTD, lower respiratory tract disease; PIV, parainfluenza virus.
Table 4. Univariable Analysis of Risk Factors for Mortality From All Causes or Respiratory Failure by Day 90 After Parainfluenza Infection Among Proven/Probable Cases (n = 121)

| Variables                        | Overall Mortality |                         | Mortality From Respiratory Failure |                         |
|----------------------------------|-------------------|--------------------------|-----------------------------------|--------------------------|
|                                  | HR (95% CI)       | P Value                  | HR (95% CI)                       | P Value                  |
| Disease category                 |                   |                          |                                   |                          |
| Probable                         | 1.00              |                          | 1.00                              |                          |
| Proven without symptoms          | 1.07 (.4–3.1)     | .91                      | 2.82 (.5–15.4)                    | .23                      |
| Proven with symptoms             | 1.61 (.8–3.4)     | .21                      | 5.19 (1.3–21.5)                   | .023                     |
| Presence of LRTD symptoms        |                   |                          |                                   |                          |
| No                               | 1.00              |                          | 1.00                              |                          |
| Yes                              | 1.39 (.6–3.2)     | .44                      | 1.54 (.6–4.3)                     | .41                      |
| Transplant year                  |                   |                          |                                   |                          |
| 1990–2000                        | 1.00              |                          | 1.00                              |                          |
| 2001–2011                        | 0.62 (.4–1.0)     | .07                      | 0.70 (.4–1.3)                     | .23                      |
| Conditioning regimen             |                   |                          |                                   |                          |
| MAC                              | 1.00              |                          | 1.00                              |                          |
| RIC                              | 0.50 (.2–1.2)     | .11                      | 0.58 (.2–1.5)                     | .26                      |
| Days between transplant and PIV infection |       |                          |                                   |                          |
| ≤365                             | 1.00              |                          | 1.00                              |                          |
| >365                             | 2.95 (1.2–7.4)    | .020                     | 5.46 (1.3–22.5)                   | .019                     |
| PIV type                         |                   |                          |                                   |                          |
| PIV-1, -2, -4                    | 1.00              |                          | 1.00                              |                          |
| PIV-3                            | 0.63 (.3–1.2)     | .18                      | 0.44 (.2–9)                       | .021                     |
| Quantitative viral load (log_{10})^{a} | 1.01 (.9–1.1)     | .84                      | 1.07 (.9–1.2)                     | .32                      |
| Diagnostic methods               |                   |                          |                                   |                          |
| Conventional methods             | 1.00              |                          | 1.00                              |                          |
| PCR alone                        | 0.10 (.3–1.1)     | .10                      | 0.59 (.3–1.3)                     | .18                      |
| Copathogen                       |                   |                          |                                   |                          |
| No                               | 1.00              |                          | 1.00                              |                          |
| Yes                              | 1.56 (1.0–2.6)    | .08                      | 1.76 (1.0–3.2)                    | .06                      |
| Oxygen at diagnosis              |                   |                          |                                   |                          |
| No                               | 2.49 (1.4–4.5)    | .002                     | 4.25 (1.9–9.5)                    | <.001                    |
| Yes                              | 1.00              |                          | 1.00                              |                          |
| Oxygen after diagnosis^{b}       |                   |                          |                                   |                          |
| ≤2 L                             | 1.00              |                          | 1.00                              |                          |
| >2 L                             | 2.09 (1.8–2.4)    | <.001                    | 2.62 (1.9–7.4)                    | .07                      |
| Mechanical ventilation           | 2.59 (2.2–3.1)    | <.001                    | 17.93 (8.7–37.0)                  | <.001                    |
| White blood cell count           |                   |                          |                                   |                          |
| >1000 cells/µL                   | 1.00              |                          | 1.00                              |                          |
| ≤1000 cells/µL                   | 2.27 (1.4–3.8)    | .002                     | 2.80 (1.6–5.1)                    | <.001                    |
| Lymphocyte count                 |                   |                          |                                   |                          |
| >300 cells/µL                    | 1.00              |                          | 1.00                              |                          |
| ≤300 cells/µL                    | 1.73 (1.1–2.9)    | .032                     | 1.82 (1.0–3.3)                    | .045                     |
| Neutrophil count                 |                   |                          |                                   |                          |
| >1000 cells/µL                   | 1.00              |                          | 1.00                              |                          |
| ≤1000 cells/µL                   | 2.35 (1.4–3.9)    | <.001                    | 2.71 (1.5–4.9)                    | <.001                    |
| Monocyte count                   |                   |                          |                                   |                          |
| >100 cells/µL                    | 1.00              |                          | 1.00                              |                          |
| ≤100 cells/µL                    | 2.30 (1.4–3.8)    | <.001                    | 2.96 (1.6–5.4)                    | <.001                    |
“probable” LRTD) is significantly worse than that of patients with PIV detection only in upper respiratory tract samples (termed “possible” LRTD) (Figure 1C and 1D). Outcomes in patients with possible LRTD were similar to that of URTI. Our study also defined important clinical risk factors associated with poor outcomes of PIV LRTD, including oxygen requirement at diagnosis, low monocyte count, and steroid use >2 mg/kg/day.

Numerous studies of respiratory viruses in immunocompromised hosts have examined LRTD either as an endpoint or a risk factor for mortality. However, previously published results for both the incidence and risk factors for progression and outcome vary widely [3–6, 11, 12]. Data presented here suggest that the variance in definitions of LRTD is one important reason for the observed differences. To address this issue, we conducted the present study to define the optimized diagnostic criteria that correlate with outcome. Based on the site of virologic detection and clinical manifestations, we classified LRTD into 3 groups (possible, probable, and proven). The recently published Fourth European Conference on Infections in Leukaemia (ECIL-4) guidelines also proposed a classification based on levels of certainty (possible, probable, confirmed) [15]. However, the ECIL-4 classification is for all respiratory viruses, applies to both UTRI and LRTD, and uses symptoms, exposure, and any viral detection (independent of site) as classifiers. In contrast, our classification is strictly among LRTD cases that were all virologically confirmed [15]. In our paper, we specifically focused on the “possible” category, which includes patients with nasopharyngeal tests demonstrating PIV infection and abnormal chest radiography, but without confirmation of virus in the lower respiratory tract. Numerous publications as well as society guidelines have generally accepted that these patients have LRTD [5–8, 11, 15–19]. Our data demonstrate that the mortality in patients with possible LRTD is significantly better than that in patients with probable and proven disease (Figure 1C and 1D) and similar to that of patients with URTI (Table 2). The effect was persistent throughout the study period (data not shown). Interestingly, possible LRTD patients without symptoms tended to have even better outcome than URTI (Supplementary Figure 1). Nevertheless, many studies include this category as LRTD [6–8, 16, 17]. Therefore, we suggest that this group we defined as “possible” LRTD should be separated from the patient group with viral detection in the lung (proven and probable LRTD cases). We developed our definitions a priori based on clinical practices across centers and the spectrum of definitions used in the literature. The “possible” and “proven” categories are by far the most common categories documented, both in our series and elsewhere. Bronchoscopy based on PIV

| Variables | Overall Mortality | Mortality From Respiratory Failure |
|-----------|------------------|----------------------------------|
| Steroid dose before diagnosis | | |
| No | 1.00 | 1.00 |
| <1 mg/kg | 1.05 (0.6–2.0) | 1.06 (5.2–2.1) | .88 |
| 1–2 mg/kg | 0.70 (0.4–1.3) | 0.62 (0.3–1.3) | .28 |
| >2 mg/kg | 3.23 (1.5–7.2) | 1.41 (4.4–8.0) | .004 |
| Steroid dose after diagnosis | | |
| No | 1.00 | 1.00 |
| <1 mg/kg | 0.64 (0.3–1.4) | 0.65 (0.3–1.5) | .24 |
| 1–2 mg/kg | 1.09 (0.6–2.1) | 1.04 (0.5–2.3) | .80 |
| >2 mg/kg | 4.39 (1.9–9.9) | 4.12 (1.8–9.7) | <.001 |
| Ribavirin use | | |
| No | 1.00 | 1.00 |
| Yes | 0.68 (0.4–1.1) | 0.95 (0.5–1.7) | .15 |
| IVIG use | | |
| No/low-dose | 1.00 | 1.00 |
| High-dose | 1.17 (0.7–2.1) | 1.29 (0.7–2.5) | .60 |

All variables in Table 1 were used for the univariable analysis. Only variables with $P < .1$ in any analysis are shown in this table. The following parameters were also shown regardless of $P$ values: presence of symptoms, quantitative viral load (log10), ribavirin use, and IVIG use.

Abbreviations: CI, confidence interval; HR, hazard ratio; IVIG, intravenous immunoglobulin; LRTD, lower respiratory tract disease; MAC, myeloablative conditioning; PCR, polymerase chain reaction; PIV, parainfluenza virus; RIC, reduced-intensity conditioning.

*a Viral titer was analyzed as a continuous variable.

*b These variables are analyzed as time dependent.

The effect was persistent throughout the study period (data not shown). Interestingly, possible LRTD patients without symptoms tended to have even better outcome than URTI (Supplementary Figure 1). Nevertheless, many studies include this category as LRTD [6–8, 16, 17]. Therefore, we suggest that this group we defined as “possible” LRTD should be separated from the patient group with viral detection in the lung (proven and probable LRTD cases). We developed our definitions a priori based on clinical practices across centers and the spectrum of definitions used in the literature. The “possible” and “proven” categories are by far the most common categories documented, both in our series and elsewhere. Bronchoscopy based on PIV
outcome appears to be similar to that seen in proven cases. Nevertheless, these patients are informative as their outcome differences seen among the probable cases in their definitions for clinical trials [20, 21]. These guidelines are widely accepted [22, 23], and resulted in improved reproducibility of study results between centers. These guidelines have greatly aided consensus endpoint definitions for clinical trials in invasive fungal disease. As new drugs for some respiratory viruses including PIV (eg, DAS181) are advancing through clinical development [24, 25], careful consideration of LRTD definitions that correlate with outcome is as important as clinical trial endpoints, entry criteria, and stratification variables.

Another novel observation of this study is that the monocyte count at diagnosis of LRTD appears to be similar to that seen in proven cases.

Although our study focused on patients infected with PIV, we hypothesize that the outcome differences seen among the “possible” disease category may also exist for other respiratory viruses. Indeed, most studies and guidelines of non-PIV respiratory viruses include “possible” cases in their definitions of LRTD [7, 15–19]. Additional studies are needed to extend these results to other respiratory virus infections. More than a decade ago, the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) established the standard definitions for invasive fungal disease [20, 21]. These guidelines detection in the upper respiratory tract and the presence of LRTD symptoms or significant signs of obstruction by spirometry (“probable” category) was performed during the 1990s at our center, but it has become very uncommon in recent years. Nevertheless, these patients are informative as their outcome appears to be similar to that seen in proven cases.

Although our study focused on patients infected with PIV, we hypothesize that the outcome differences seen among the “possible” disease category may also exist for other respiratory viruses. Indeed, most studies and guidelines of non-PIV respiratory viruses include “possible” cases in their definitions of LRTD [7, 15–19]. Additional studies are needed to extend these results to other respiratory virus infections. More than a decade ago, the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) established the standard definitions for invasive fungal disease [20, 21]. These guidelines

### Table 5. Multivariable Analysis of Risk Factors for Mortality From All Causes or Respiratory Failure by Day 90 After Diagnosis in Proven/Probable Cases (n = 121)

| Final Model | Steroid Dose | Ribavirin | IVIG |
|-------------|--------------|-----------|------|
| **Overall mortality** | | | |
| Oxygen at diagnosis (yes vs no) | 2.44 (1.3–4.4) .003 | 2.19 (1.2–4.1) .013 | 2.28 (1.4–4.2) .007 | 2.63 (1.5–4.8) .001 |
| Days between transplant and PIV infection (≤365 vs >365) | 2.26 (1.9–5.8) .09 | 2.46 (1.6–6.3) .06 | 2.34 (1.6–6.7) .08 |
| Transplant year | 0.72 (.4–1.2) .22 | 0.88 (.4–1.5) .16 | 0.77 (.4–1.3) .34 |
| Monocyte count (<100 vs ≥100 cells/µL) | 1.63 (1–9.2) .09 | 2.33 (1.4–4.0) .002 | 1.97 (1.2–3.3) .010 |
| Neutrophil count (<1000 vs ≥1000 cells/µL) | 1.58 (.9–2.8) .12 | | |
| Steroid dose after diagnosis (≥2 vs ≤2 mg/kg) | 3.80 (2–7.4) <.001 | | |
| Ribavirin use (yes vs no) | 0.51 (.3–.9) .021 | | |
| IVIG use (high-dose vs no/low-dose) | 0.99 (.5–1.8) .97 | | |

**Abbreviations**: CI, confidence interval; HR, hazard ratio; IVIG, intravenous immunoglobulin; PIV, parainfluenza virus.

*These variables are analyzed as time dependent.*
particularly high mortality (Figure 3). Monocytes have been known to be important to protect from viral infections [27–31]. Neutrophils may also have an important role at the time of pneumonia, and these 2 cells interact with each other [32–34]. These data from basic research support our finding that monocytes and neutrophils are important for outcomes after LRTD.

This is the first outcome study of PIV that used multivariable modeling for evaluating treatment strategies. Previous studies suggested that steroid use was associated with high mortality [5, 6, 12]. Our results showed that steroid use of ≤2 mg/kg/day after PIV LRTD was not associated with mortality. Based on our results, high-dose steroids for acute lung injury are not recommended, and a rapid taper of steroids for graft-vs-host disease may not be required when lower doses are used.

Because no antiviral drug is currently approved for the treatment of PIV disease, ribavirin and IVIG are often used off-label in PIV LRTD cases. Previous reports showed conflicting results ranging from no apparent efficacy on mortality after PIV LRTD [3–6, 12, 35], to moderate efficacy [36–39]. Most studies had a small sample size, and no statistical adjustments were made for disease severity. Thus, the effect of ribavirin is still controversial [40]. Our results show conflicting results for ribavirin treatment. Although the overall mortality model suggested a survival benefit among patients with proven and probable LRTD (Table 5), no significant effect was seen for death due to respiratory failure and for patients with proven LRTD. Some important variables such as high-dose steroids or the effect of combination therapy with IVIG could not be adequately assessed due to the small number of the patients with proven/probable LRTD who received these treatment combinations.

Recently, PCR testing has become more widely utilized as a diagnostic method and the frequency of diagnoses of viral infections has been increasing [13]. However, the association of quantitative RNA viral load on mortality after PIV LRTD has not been well evaluated. In our study, BAL samples that were also positive by conventional methods generally had a higher viral load (Supplementary Figure 2A), consistent with previous reports in nasal wash samples [13]. The results also show that the “proven” and “probable” disease categories do not differ with regard to viral load and that the presence of clinical LRTD symptoms was not associated with higher viral load (Supplementary Figure 2B). These findings provide support for combining both groups in outcome analyses, as proposed in this study. Our results did not identify RNA viral load in the BAL as a significant factor for mortality, although the number of subjects with available viral load was relatively small.

This study has several limitations. Although this study is the largest cohort of confirmed PIV infections in HCT recipients (which includes our previously reported cases [4] as well as subsequent cases through 2011), the sample size was still not sufficient to perform multivariable analyses to evaluate the impact of LRTD disease categories or the effect of combination of several drugs on mortality. Because of the retrospective nature of the study, BAL samples were available in only half of the patients for viral load quantification, which limited the multivariable modeling. The use of bronchoscopy for the workup of LRTD is largely based on protocols at our center, with almost all patients undergoing this procedure when radiographic signs or LRTD symptoms occur. Nevertheless, the final decision to perform bronchoscopy rests with the attending physician and some patients may not have undergone this procedure. Therefore, some probable or proven cases may have been missed, but this is unlikely to affect the major results of this study.

![Figure 3](https://example.com/figure3.png)

**Figure 3.** Probability of overall survival and death caused by respiratory failure according to monocyte count and oxygen requirement in proven/probable lower respiratory tract disease (LRTD) cases. A, Kaplan-Meier estimate of overall survival by monocyte count and oxygen requirement in proven/probable cases (P<.001). B, Cumulative incidence of death caused by respiratory failure according to LRTD classification in proven/probable cases (P<.001).
In conclusion, our data demonstrate that patients with PIV detection in the lungs (proven/probable LRTD) had worse outcomes compared with those with PIV detection in nasopharyngeal samples alone (possible LRTD). The outcome of possible LRTD was comparable to that of URTI. This LRTD definition could be useful for future outcome studies independent of virus types, and studies are needed to validate the results for other viruses and immunocompromised host settings. Consensus definitions in accordance with outcomes should be developed for respiratory viral disease.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyrighted. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank Zachary Stednick for database services, Terry Stevens-Ayers and Elsa Garnace for laboratory assistance, and Louise E. Kimball, Farah T. Saooh, and Sonia Goyal for data collection.

Financial support. This work was supported by the National Institutes of Health (grant numbers CA18029, CA15704, HL081595, HL93294, K23HL091059, and L40AI071572) and Ansun Biopharma, Inc. S. S. is a recipient of a fellowship from the Joel Meyers Memorial Fund. A. P. C. also received K23HL091059, and L40AI071572) and Ansun Biopharma, Inc. S. S. is a recipient of a fellowship from the Joel Meyers Memorial Fund. A. P. C. also received

Potential conflicts of interest. M. B. has received research support from Ansun Biopharma, Inc. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis 2011; 24:333–43.
2. Shah DP, Ghantoji SS, Mulanovich VE, Ariza-Heredia EJ, Chemaly RF. Management of respiratory viral infections in hematopoietic cell transplant recipients. Am J Blood Res 2012; 2:203–18.
3. Elizaga J, Olavarria E, Apperley J, Goldman J, Ward K. Parainfluenza virus 3 infection after stem cell transplantation: relevance to outcome of rapid diagnosis and ribavirin treatment. Clin Infect Dis 2001; 32:413–8.
4. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001; 98:573–8.
5. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood 2012; 119:2738–45; quiz 969.
6. Ustun C, Slaby J, Shanley RM, et al. Human parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, management, mortality, and changes over time. Biol Blood Marrow Transplant 2012; 18:1580–8.
7. El Saleeby CM, Somes GW, DeVincenzo JP, Gaur AH. Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age. Pediatrics 2008; 121:235–43.
8. Ljunghman P, de la Camara R, Perez-Bercoff L, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011; 96:1231–5.
9. Milano F, Campbell AP, Guthrie KA, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. Blood 2010; 115:2088–94.
10. Cortez KJ, Erdman DD, Peret TC, et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001; 184:1093–7.
11. Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K. A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. Bone Marrow Transplant 2011; 46:1545–50.
12. Srinivasan A, Wang C, Yang C, Jiang JL, Leung WH, Hayden RT. Symptomatic parainfluenza virus infections in children undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17:1520–7.
13. Kuypers J, Campbell AP, Cent A, Corey L, Boeckh M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis 2009; 11:299–303.
14. Seo S, Campbell AP, Xie H, et al. Outcome of respiratory syncytial virus lower respiratory tract disease in hematopoietic cell transplant recipients receiving aerosolized ribavirin: significance of stem cell source and oxygen requirement. Biol Blood Marrow Transplant 2013; 19:589–96.
15. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljunghman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013; 56:258–66.
16. Ljunghman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28:479–84.
17. Mohy B, Thomas Y, Vukicevic M, et al. Clinical features and outcome of 2009-influenza A (H1N1) after allogeneic hematopoietic SCT. Bone Marrow Transplant 2012; 47:236–42.
18. Machado CM, Boas LS, Mendes AV, et al. Use of oseltamivir to control influenza complications after bone marrow transplantation. Bone Marrow Transplant 2004; 34:111–4.
19. Small TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29:321–7.
20. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7–14.
21. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46:1813–21.
22. Bergeron A, Porcher R, Sulahian A, et al. The strategy for the diagnosis of invasive pulmonary aspergillosis should depend on both the underlying condition and the leukocyte count of patients with hematologic malignancies. Blood 2012; 119:1831–7; quiz 956.
23. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50:1101–11.
24. Chen YB, Driscoll JP, McAfee SL, et al. Treatment of parainfluenza 3 infection with DAS181 in a patient after allogeneic hematopoietic SCT. Blood 2011; 73:1510–4.
25. Drozd DR, Limaye AP, Moss RB, et al. DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient. Transpl Infect Dis 2013; 15:E28–32.
26. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother 2013; 68:1872–80.

27. Kumagai Y, Takeuchi O, Akira S. Pathogen recognition by innate receptors. J Infect Chemother 2008; 14:86–92.

28. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev 2009; 227:75–86.

29. Cros J, Cagnard N, Woolard K, et al. Human CD14dim monocytes patrol and sense nucleic acids and viruses via TLR7 and TLR8 receptors. Immunity 2010; 33:375–86.

30. Barbalat R, Lau L, Locksley RM, Barton GM. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009; 10:1200–7.

31. Tang L, Li Q, Bai J, Zhang H, Lu Y, Ma S. Severe pneumonia mortality in elderly patients is associated with downregulation of Toll-like receptors 2 and 4 on monocytes. Am J Med Sci 2014; 347:34–41.

32. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11:519–31.

33. Janardhan KS, Sandhu SK, Singh B. Neutrophil depletion inhibits early and late monocyte/macrophage increase in lung inflammation. Front Biosci 2006; 11:1569–76.

34. Kaplanis G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol 2003; 24:25–9.

35. Lewis VA, Champlin R, Englund J, et al. Respiratory disease due to parainfluenza virus in adult bone marrow transplant recipients. Clin Infect Dis 1996; 23:1033–7.

36. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D, Milligan DW. Parainfluenza virus type 3 infections in hematopoietic stem cell transplant recipients: response to ribavirin therapy. Clin Infect Dis 2000; 31:1516–8.

37. Dignan F, Alvares C, Riley U, et al. Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality. J Hosp Infect 2006; 63:452–8.

38. Chakrabarti S, Collingham KE, Holder K, Fegan CD, Osman H, Milligan DW. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2001; 28:759–63.

39. Sparrelid E, Ljungman P, Ekelof-Andstrom E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant 1997; 19:905–8.

40. Falsey AR. Current management of parainfluenza pneumonitis in immunocompromised patients: a review. Infect Drug Resist 2012; 5:121–7.